BC Innovations | Nov 7, 2019
Targets & Mechanisms

New cereblon substrates linked to thalidomide teratogenicity

A Celgene-funded study from Tokyo Medical University and the University of Milan has identified two new thalidomide-dependent CRBN substrates that could be applied to screens for new, safer thalidomide derivatives. Thalidomide and its analogs, collectively...
BC Week In Review | Mar 1, 2019
Company News

Celgene products drive BeiGene 4Q revenue gains

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) reported its 4Q18 earnings late Feb. 27 with revenue gains driven by its in-licensed products from Celgene Corp. (NASDAQ:CELG). BeiGene's portfolio includes Chinese rights to cancer drugs Abraxane nab-paclitaxel, Revlimid lenalidomide...
BC Extra | Feb 28, 2019
Financial News

Celgene products drive BeiGene 4Q revenue gains

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) reported its 4Q18 earnings late Wednesday with revenue gains driven by its in-licensed products from Celgene Corp. (NASDAQ:CELG). BeiGene's portfolio includes Chinese rights to cancer drugs Abraxane nab-paclitaxel, Revlimid lenalidomide and...
BioCentury | Jan 27, 2018
Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
BC Week In Review | Dec 1, 2017
Company News

ArcherDX to develop companion diagnostic for CC-122

ArcherDx Inc. (Boulder, Colo.) will develop and commercialize a companion diagnostic to identify diffuse B cell lymphoma patients who may best respond to CC-122 from Celgene Corp. (NASDAQ:CELG). CC-122 is a cancer pleiotropic pathway modifier...
BC Innovations | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
BC Week In Review | Jul 7, 2017
Company News

BeiGene grants Celgene PD-1 rights, acquires China operations

BeiGene Ltd. (NASDAQ:BGNE) granted Celgene Corp. (NASDAQ:CELG) exclusive rights in most of the world to its PD-1 inhibitor BGB-A317 for non-hematological indications and acquired Celgene's commercial operations in China, including local rights to a handful...
BC Extra | Jul 7, 2017
Company News

BeiGene grants Celgene PD-1 rights, acquires China operations

BeiGene Ltd. (NASDAQ:BGNE) granted Celgene Corp. (NASDAQ:CELG) exclusive rights in most of the world to its PD-1 inhibitor BGB-A317 for non-hematological indications and acquired Celgene's commercial operations in China, including local rights to a handful...
BC Innovations | Apr 9, 2015
Distillery Therapeutics

Therapeutics: An undetermined target

Cancer INDICATION: Multiple myeloma (MM); hematologic malignancies Cell culture and mouse studies suggest a deuterium-containing enantiomer of the racemic compound CC-122 could help treat MM and other hematologic malignancies more effectively than CC-122. Chemical synthesis...
Items per page:
1 - 10 of 11